186 related articles for article (PubMed ID: 37026013)
1. Convalescent human IgG, but not IgM, from COVID-19 survivors confers dose-dependent protection against SARS-CoV-2 replication and disease in hamsters.
King HAD; Dussupt V; Mendez-Rivera L; Slike BM; Tran U; Jackson ND; Barkei E; Zemil M; Tourtellott-Fogt E; Kuklis CH; Soman S; Ahmed A; Porto M; Kitajewski C; Spence B; Benetiene D; Wieczorek L; Kar S; Gromowski G; Polonis VR; Krebs SJ; Modjarrad K; Bolton DL
Front Immunol; 2023; 14():1138629. PubMed ID: 37026013
[TBL] [Abstract][Full Text] [Related]
2. Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.
Takamatsu Y; Imai M; Maeda K; Nakajima N; Higashi-Kuwata N; Iwatsuki-Horimoto K; Ito M; Kiso M; Maemura T; Takeda Y; Omata K; Suzuki T; Kawaoka Y; Mitsuya H
J Virol; 2022 Feb; 96(4):e0155121. PubMed ID: 34818068
[TBL] [Abstract][Full Text] [Related]
3. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.
Su W; Sia SF; Schmitz AJ; Bricker TL; Starr TN; Greaney AJ; Turner JS; Mohammed BM; Liu Z; Choy KT; Darling TL; Joshi A; Cheng KM; Wong AYL; Harastani HH; Nicholls JM; Whelan SPJ; Bloom JD; Yen HL; Ellebedy AH; Boon ACM
mBio; 2021 Oct; 12(5):e0239521. PubMed ID: 34517754
[TBL] [Abstract][Full Text] [Related]
4. Absence of Vaccine-enhanced Disease With Unexpected Positive Protection Against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by Inactivated Vaccine Given Within 3 Days of Virus Challenge in Syrian Hamster Model.
Li C; Chen YX; Liu FF; Lee AC; Zhao Y; Ye ZH; Cai JP; Chu H; Zhang RQ; Chan KH; Chiu KH; Lung DC; Sridhar S; Hung IF; To KK; Zhang AJ; Chan JF; Yuen KY
Clin Infect Dis; 2021 Aug; 73(3):e719-e734. PubMed ID: 33515458
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic equine hyperimmune antibodies with high and broad-spectrum neutralizing activity protect rodents against SARS-CoV-2 infection.
Li E; Han Q; Bi J; Wei S; Wang S; Zhang Y; Liu J; Feng N; Wang T; Wu J; Yang S; Zhao Y; Liu B; Yan F; Xia X
Front Immunol; 2023; 14():1066730. PubMed ID: 36875106
[TBL] [Abstract][Full Text] [Related]
8. A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model.
Ma J; Liu X; Zhou M; Chen P; Chen R; Wang J; Zhu H; Wu K; Ye J; Zhang Y; Yuan Q; Tang Q; Yuan L; Cheng T; Guan Y; Xia N
J Virol; 2023 Feb; 97(2):e0168422. PubMed ID: 36651747
[TBL] [Abstract][Full Text] [Related]
9. Brief Research Report: Virus-Specific Humoral Immunity at Admission Predicts the Development of Respiratory Failure in Unvaccinated SARS-CoV-2 Patients.
Tajuelo A; Carretero O; García-Ríos E; López-Siles M; Cano O; Vázquez M; Más V; Rodríguez-Goncer I; Lalueza A; López-Medrano F; Juan RS; Fernández-Ruiz M; Aguado JM; McConnell MJ; Pérez-Romero P
Front Immunol; 2022; 13():878812. PubMed ID: 35547738
[TBL] [Abstract][Full Text] [Related]
10. Mucosal immunization with Ad5-based vaccines protects Syrian hamsters from challenge with omicron and delta variants of SARS-CoV-2.
Braun MR; Martinez CI; Dora EG; Showalter LJ; Mercedes AR; Tucker SN
Front Immunol; 2023; 14():1086035. PubMed ID: 36911687
[TBL] [Abstract][Full Text] [Related]
11. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development.
Imai M; Iwatsuki-Horimoto K; Hatta M; Loeber S; Halfmann PJ; Nakajima N; Watanabe T; Ujie M; Takahashi K; Ito M; Yamada S; Fan S; Chiba S; Kuroda M; Guan L; Takada K; Armbrust T; Balogh A; Furusawa Y; Okuda M; Ueki H; Yasuhara A; Sakai-Tagawa Y; Lopes TJS; Kiso M; Yamayoshi S; Kinoshita N; Ohmagari N; Hattori SI; Takeda M; Mitsuya H; Krammer F; Suzuki T; Kawaoka Y
Proc Natl Acad Sci U S A; 2020 Jul; 117(28):16587-16595. PubMed ID: 32571934
[TBL] [Abstract][Full Text] [Related]
12. IgM antibodies derived from memory B cells are potent cross-variant neutralizers of SARS-CoV-2.
Hale M; Netland J; Chen Y; Thouvenel CD; Smith KN; Rich LM; Vanderwall ER; Miranda MC; Eggenberger J; Hao L; Watson MJ; Mundorff CC; Rodda LB; King NP; Guttman M; Gale M; Abraham J; Debley JS; Pepper M; Rawlings DJ
J Exp Med; 2022 Sep; 219(9):. PubMed ID: 35938988
[TBL] [Abstract][Full Text] [Related]
13. Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern.
Mohandas S; Yadav PD; Sapkal G; Shete AM; Deshpande G; Nyayanit DA; Patil D; Kadam M; Kumar A; Mote C; Jain R
EBioMedicine; 2022 May; 79():103997. PubMed ID: 35405385
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a new SARS-CoV-2 variant that emerged in Brazil.
Imai M; Halfmann PJ; Yamayoshi S; Iwatsuki-Horimoto K; Chiba S; Watanabe T; Nakajima N; Ito M; Kuroda M; Kiso M; Maemura T; Takahashi K; Loeber S; Hatta M; Koga M; Nagai H; Yamamoto S; Saito M; Adachi E; Akasaka O; Nakamura M; Nakachi I; Ogura T; Baba R; Fujita K; Ochi J; Mitamura K; Kato H; Nakajima H; Yagi K; Hattori SI; Maeda K; Suzuki T; Miyazato Y; Valdez R; Gherasim C; Furusawa Y; Okuda M; Ujie M; Lopes TJS; Yasuhara A; Ueki H; Sakai-Tagawa Y; Eisfeld AJ; Baczenas JJ; Baker DA; O'Connor SL; O'Connor DH; Fukushi S; Fujimoto T; Kuroda Y; Gordon A; Maeda K; Ohmagari N; Sugaya N; Yotsuyanagi H; Mitsuya H; Suzuki T; Kawaoka Y
Proc Natl Acad Sci U S A; 2021 Jul; 118(27):. PubMed ID: 34140350
[TBL] [Abstract][Full Text] [Related]
15. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
16. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
Scaggs Huang F
J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
[TBL] [Abstract][Full Text] [Related]
17. Efficient and Sustainable Platform for Preparation of a High-Quality Immunoglobulin G as an Urgent Treatment Option During Emerging Virus Outbreaks.
Kurtović T; Ravlić S; Štimac A; Mateljak Lukačević S; Hećimović A; Kazazić S; Halassy B
Front Immunol; 2022; 13():889736. PubMed ID: 35655779
[TBL] [Abstract][Full Text] [Related]
18. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort.
Zhang S; Xu K; Li C; Zhou L; Kong X; Peng J; Zhu F; Bao C; Jin H; Gao Q; Zhao X; Zhu L
Front Immunol; 2022; 13():829665. PubMed ID: 35154152
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 Kappa Variant Shows Pathogenicity in a Syrian Hamster Model.
Yadav PD; Mohandas S; Shete AM; Nyayanit DA; Gupta N; Patil DY; Sapkal GN; Potdar V; Kadam M; Kumar A; Kumar S; Suryavanshi D; Mote CS; Abraham P; Panda S; Bhargava B
Vector Borne Zoonotic Dis; 2022 May; 22(5):289-296. PubMed ID: 35580212
[No Abstract] [Full Text] [Related]
[Next] [New Search]
